You are here: Industry Insights > cardiovascular

News List

The protective effect of soluble guanylate cyclase activators on the cardiovascular system and their therapeutic mechanism for HFpEF Xiaomichong
July 17, 2024
The impairment of the nitric oxide (NO) pathway is closely related to various cardiovascular diseases, such as heart failure, hypertension, and pulmonary hypertension. NO donor drugs or inhaled NO have significant limitations in clinical treatment.
Clinical Decision Support May Cut Cardiovascular Disease Risk drugs.com
February 10, 2022
Use of clinical decision support systems (CDSSs) is associated with improvements in reversible risk for cardiovascular disease.
Midlife CV Conditions, Risk Factors Linked to Cognitive Decline drugs
January 05, 2022
Midlife cardiovascular conditions and risk factors are associated with cognitive decline, with stronger associations for women, according to a study published online Jan. 5 in Neurology.
Amgen, Owkin Use AI to Improve Cardiovascular Risk Prediction contractpharma
December 17, 2021
Study demonstrates the ability of AI to improve the way clinicians predict patients' risk of suffering major cardiovascular events.
Birth Order, Family Size May Affect Heart Health drugs
May 27, 2021
A new Swedish study found that first-born children had a lower risk of heart attacks and strokes than their younger brothers and sisters. But having many siblings was associated with an increased risk of such cardiovascular events.
Intensive BP Lowering Cuts Major Adverse CV Events, Mortality drugs
May 21, 2021
Intensive blood pressure treatment targeting systolic blood pressure <120 mm Hg results in lower rates of major adverse cardiovascular events and lower all-cause mortality than a standard treatment target among patients at increased cardiovascular risk
MHRA authorises Amarin’s heart drug Vazkepa pharmatimes
April 23, 2021
Amarin’s Vazkepa has received authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) as a treatment to reduce the risk of cardiovascular (CV) events in high-risk patients.
Takeda to divest select assets in China to Hasten Biopharmaceutic for $322 mn expresspharma
December 22, 2020
Takeda Pharmaceutical Company has entered into an agreement to divest a portfolio of non-core prescription pharma products sold in China to Hasten Biopharmaceutic (China).
Zydus Cadila gets tentative US FDA approval for Dapagliflozin Tablets expresspharma
October 30, 2020
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated to improve glycemic control in adults with type 2 diabetes mellitus.
Takeda sells select non-core assets in Europe to Cheplapharm for about $562 mn expresspharma
September 17, 2020
Portfolio includes prescription products in Takeda’s cardiovascular/metabolic and anti-inflammatory therapeutic areas along with calcium.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page